Pablo Tamayo

Pablo Tamayo

Auto-generated profile, based on publicly available information

Pablo Tamayo

Moores Cancer Center, UC San Diego, La Jolla, CA, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Cell Systems
Verified
Journal Article
Closed access
ALArthur Liberzon
Arthur Liberzon
CBChet Birger
Chet Birger
HTHelga Thorvaldsdóttir
Helga Thorvaldsdóttir
MGMahmoud Ghandi
Mahmoud Ghandi
JMJill P. Mesirov
Jill P. Mesirov
PTPablo Tamayo
Pablo Tamayo

29 February 2016 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
CYChanning Yu
Channing Yu
AMAristotle M Mannan
Aristotle M Mannan
GYGriselda Metta Yvone
Griselda Metta Yvone
KRKenneth N Ross
Kenneth N Ross
YZYan-Ling Zhang
Yan-Ling Zhang
TGTodd R Golub
Todd R Golub
A method called PRISM rapidly identifies drug candidates that are effective against specific cancer cell lines. Hundreds of genetically characterized cell lines are available for the discovery of genotype-specific cancer vulnerabilities. However, screening large numbers of compounds against large numbers of cell lines is currently impractical, and such experiments are often difficult to control1,2,3,4. Here we report a method called PRISM that allows pooled screening of mixtures of cancer cell lines by labeling each cell line with 24-nucleotide barcodes. PRISM revealed the expected patterns of cell killing seen in conventional (unpooled) assays. In a screen of 102 cell lines across 8,400 compounds, PRISM led to the identification of BRD-7880 as a potent and highly specific inhibitor of aurora kinases B and C. Cell line pools also efficiently formed tumors as xenografts, and PRISM recapitulated the expected pattern of erlotinib sensitivity in vivo.

23 July 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ICIsrael Cañadas
Israel Cañadas
RTRohit Thummalapalli
Rohit Thummalapalli
JKJong Wook Kim
Jong Wook Kim
SKShunsuke Kitajima
Shunsuke Kitajima
RJRussell W. Jenkins
Russell W. Jenkins
DBDavid A Barbie
David A Barbie


21 November 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MIMichael S. Isakoff
Michael S. Isakoff
CSCourtney G. Sansam
Courtney G. Sansam
PTPablo Tamayo
Pablo Tamayo
ASAravind Subramanian
Aravind Subramanian
JEJulia A. Evans
Julia A. Evans
CRCharles W. M. Roberts
Charles W. M. Roberts
Snf5 (Ini1/Baf47/Smarcb1), a core member of the Swi/Snf chromatin remodeling complex, is a potent tumor suppressor whose mechanism of action is largely unknown. Biallelic loss of Snf5 leads to the onset of aggressive cancers in both humans and mice. We have developed an innovative and widely applicable analytical technique for cross-species validation of cancer models and show that the gene expression profiles of our Snf5 murine models closely resemble those of human Snf5-deficient rhabdoid tumors. We exploit this system to produce what we believe to be the first report documenting the effects on gene expression of inactivating a Swi/Snf subunit in normal mammalian cells and to identify the transcriptional pathways regulated by Snf5. We demonstrate that the tumor suppressor activity of Snf5 depends on its regulation of cell cycle progression; Snf5 inactivation leads to aberrant up-regulation of E2F targets and increased levels of p53 that are accompanied by apoptosis, polyploidy, and growth arrest. Further, conditional mouse models demonstrate that inactivation of p16Ink4a or Rb (retinoblastoma) does not accelerate tumor formation in Snf5 conditional mice, whereas mutation of p53 leads to a dramatic acceleration of tumor formation.

9 July 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
DMDaniel Martin
Daniel Martin
MDMaria S. Degese
Maria S. Degese
LVLynn Vitale-Cross
Lynn Vitale-Cross
RIRamiro Iglesias-Bartolome
Ramiro Iglesias-Bartolome
JVJuan Luis Callejas Valera
Juan Luis Callejas Valera
JGJ.Silvio Gutkind
J.Silvio Gutkind
Dysregulation of the Hippo signaling pathway and the consequent YAP1 activation is a frequent event in human malignancies, yet the underlying molecular mechanisms are still poorly understood. A pancancer analysis of core Hippo kinases and their candidate regulating molecules revealed few alterations in the canonical Hippo pathway, but very frequent genetic alterations in the FAT family of atypical cadherins. By focusing on head and neck squamous cell carcinoma (HNSCC), which displays frequent FAT1 alterations (29.8%), we provide evidence that FAT1 functional loss results in YAP1 activation. Mechanistically, we found that FAT1 assembles a multimeric Hippo signaling complex (signalome), resulting in activation of core Hippo kinases by TAOKs and consequent YAP1 inactivation. We also show that unrestrained YAP1 acts as an oncogenic driver in HNSCC, and that targeting YAP1 may represent an attractive precision therapeutic option for cancers harboring genomic alterations in the FAT1 tumor suppressor genes.